Kamada (KMDA) Cash from Investing Activities (2012 - 2026)
Kamada's (KMDA) quarterly Cash from Investing Activities came in at -$2.5 million in Q2 2026, down 26.22% on a YoY basis from -$3.4 million in Q2 2025, and up 93.83% quarter-over-quarter from -$41.2 million in Q1 2026.
Analysis
Kamada (KMDA) Cash from Investing Activities (2012 - 2026) Analysis & Trends
Kamada (KMDA) has reported Cash from Investing Activities for 15 consecutive years, with -$2.5 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Cash from Investing Activities fell 26.22% year-over-year to -$2.5 million; the trailing twelve-month figure through Jun 2026 stood at -$50.1 million (down 487.94% YoY), and the FY2025 full-year result was -$9.8 million, up 8.39% from the prior year.
- Cash from Investing Activities climbed to -$2.5 million in Q2 2026 per KMDA's latest filing, from -$41.2 million in the prior quarter.
- Across five years, Cash from Investing Activities topped out at -$513000.0 in Q1 2022 and bottomed at -$41.2 million in Q1 2026.
- Historically, Cash from Investing Activities has averaged -$4.1 million across 5 years, with a median of -$2.0 million in 2023.
- The sharpest annual moves came in 2022 and 2026: Cash from Investing Activities soared 98.98% in 2022, then sank 2721.78% in 2026.
- Over 5 years, Cash from Investing Activities stood at -$977000.0 in 2022, then slumped by 101.94% to -$2.0 million in 2023, then plunged by 48.2% to -$2.9 million in 2024, then rose by 5.1% to -$2.8 million in 2025, then increased by 8.4% to -$2.5 million in 2026.
- According to Business Quant data, Cash from Investing Activities over the past three periods registered -$2.5 million, -$41.2 million, and -$2.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | -569.00 Mn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | -10.35 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | -45.80 Mn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | -92.70 Mn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | 329.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | -363.46 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | -3.84 Bn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | 281.26 Mn |
| 10 | Kamada | 473.57 Mn | 403.43 Mn | 22.47 Mn | -2.54 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -2.54 Mn |
| Mar 31, 2026 | -41.20 Mn |
| Dec 31, 2025 | -2.78 Mn |
| Sep 30, 2025 | -3.59 Mn |
| Jun 30, 2025 | -2.01 Mn |
| Mar 31, 2025 | -1.46 Mn |
| Dec 31, 2024 | -2.92 Mn |
| Sep 30, 2024 | -2.12 Mn |
| Jun 30, 2024 | -3.01 Mn |
| Mar 31, 2024 | -2.68 Mn |
| Dec 31, 2023 | -1.97 Mn |
| Sep 30, 2023 | -1.73 Mn |
| Jun 30, 2023 | -1.05 Mn |
| Mar 31, 2023 | -1.09 Mn |
| Dec 31, 2022 | -977,000.00 |
| Sep 30, 2022 | -1.62 Mn |
| Jun 30, 2022 | -678,000.00 |
| Mar 31, 2022 | -513,000.00 |
| Dec 31, 2021 | -95.74 Mn |
| Sep 30, 2021 | 34.59 Mn |